▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

XMFEBCapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Jul 14, 2015 by Todd Campbell

Midyear Report Card: Grading My Biotech Predictions for 2015

One Foolish investor shines a bright light on his biotech stocks predictions for this year.

Jul 13, 2015 by Todd Campbell

ImmunoGen, Inc.'s Shares Jumped Another 15% Today

Immunogen shares continue to advance on the heels of positive trial data last month.

Jul 13, 2015 by Todd Campbell

5 Drugs That Investors May Be Undervaluing

One Foolish investor thinks these five drugs could send shares in these companies higher.

Jul 11, 2015 by Todd Campbell

3 Things You Should Know About Amarin Plc

Amarin Plc has important catalysts that investors ought to know about before buying its shares.

Jul 11, 2015 by Todd Campbell

Pfizer's Next-Generation Human Growth Hormone Takes a Step Forward

Enrollment is complete in Pfizer and Opko Health's phase 3 study of hGH-CTP for human growth hormone deficiency.

Jul 11, 2015 by Todd Campbell

Why Shares in Medivation Inc. Tumbled Over 10% in June

The reason behind Medivation Inc.'s June share price tumble

Jul 10, 2015 by Todd Campbell

3 Long Shots Biotech Companies Are Working On

These companies are developing new treatments for Alzheimer's disease and Parkinson's disease that could bring in billions if they succeed.

Jul 9, 2015 by Todd Campbell and Michael Douglass

This Week's Top Healthcare News Could Cause These Stocks Pop or Drop

Novartis nabs approval for a drug that could revolutionize how we treat heart disease and CVS Health doubles down on its anti-tobacco stance. Today we discuss what it means for the companies involved.

Jul 9, 2015 by Todd Campbell

What Is the Potential Impact of Gilead's Harvoni Launching in Japan?

Gilead Sciences' Harvoni has won regulatory approval for use in Japan.

Jul 9, 2015 by Todd Campbell

Why Shares in Dynavax Technologies Corp Are Soaring 10% Higher Today

Dynavax Technologies Corp.'s shares jump on news that its phase 3 trial for HEPLISAV-B will continue.

Jul 9, 2015 by Todd Campbell

Why Shares in Exact Sciences Soared 10% Higher in June

A new collaboration and second quarter guidance propelled Exact Sciences shares higher in June.

Jul 9, 2015 by Todd Campbell

The FDA Breathes New Life Into Esperion's ETC-1002

The FDA removed a headwind that has been holding back enthusiasm for ETC-1002, but questions still remain.

Jul 9, 2015 by Todd Campbell

Horizon's Hostile Bid for DepoMed Is Too Low

Horizon Pharma plc's $3 billion offer to acquire DepoMed isn't big enough.

Jul 8, 2015 by Todd Campbell

Why Shares in Bluebird Bio Slumped By More Than 10% in June

An ending of bluebird bio and Celgene Corp's collaboration on CAR-T therapies weighed on shares last month.

Jul 7, 2015 by Todd Campbell

Why Shares in DepoMed Inc. Are Charging 35% Higher

Horizon Pharma plc has made a hostile bid to acquire DepoMed Inc.

female_scientist_microscope

Oct 9, 2018 by Todd Campbell

3 Biotech Stocks Working On CAR-T Immunotherapy You Ought to Watch

Juno Therapeutics, Kite Pharma, and Ziopharm Oncology are developing an entirely new way to battle cancer.

Jul 5, 2015 by Todd Campbell

Biotech Billionaires: Can They Do It Again?

Phillip Frost, Lonnie Moulder, and Patrick Soon-Shiong have made billions of dollars for their investors in the past. That may mean that their latest projects are worth watching.

Jul 5, 2015 by Todd Campbell

3 Moneymaking Biotech Stocks to Consider Buying

One Foolish contributor shares three intriguing and profitable biotech companies that have caught his eye.

Jul 4, 2015 by Todd Campbell

Why Shares of Prothena Surged 33% Higher in June

Early stage trial results for Prothena's PRX002 sent shares higher last month.

Jul 4, 2015 by Todd Campbell

Why Shares in Amicus Therapeutics Shot Higher in June

Amicus Therapeutics shares jumped on news that it had filed for European approval of Galafold, a therapy for Fabry disease.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services